Celgene (BUE:CELG) E10: ARS0.00 (As of Sep. 2019)


What is Celgene E10?

Celgene BUE:CELG 10 E10 is ARS0.00 as of Sep. 2019. GuruFocus rates BUE:CELG with a GF Score™ of 10/100. The stock has 1 warning sign investors should review.

Note: As E10 is a main component used to calculate Shiller PE Ratio. If the month end stock price for this stock is zero, result may not be accurate due to the exchange rate between different shares and the data will not be stored into our database. Selected historical data showed in the calculation sectione below is only for demostration purpose.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

Celgene's adjusted earnings per share data for the three months ended in Sep. 2019 was ARS129.748. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is ARS0.00 for the trailing ten years ended in Sep. 2019.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

As of today (2026-07-08), Celgene's current stock price is ARS0.00. Celgene's E10 for the quarter that ended in Sep. 2019 was ARS0.00. Celgene's Shiller PE Ratio of today is .

During the past 13 years, the highest Shiller PE Ratio of Celgene was 135.10. The lowest was 87.09. And the median was 110.93.


Celgene  (BUE:CELG) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.

During the past 13 years, the highest Shiller P/E Ratio of Celgene was 135.10. The lowest was 87.09. And the median was 110.93.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


Celgene E10 Related Terms


Celgene E10 Historical Data

* Premium members only.

The historical data trend for Celgene's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Celgene E10 Chart

Celgene Annual Data
Trend Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Celgene Quarterly Data
Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

BUE:CELG vs GILD, BIIB, ACT: E10 Comparison

For the Drug Manufacturers - General subindustry, Celgene's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Celgene Shiller PE Ratio vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Celgene's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where Celgene's Shiller PE Ratio falls into.



Celgene E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Celgene's adjusted earnings per share data for the three months ended in Sep. 2019 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Sep. 2019 (Change)*Current CPI (Sep. 2019)
=129.748/256.7590*256.7590
=129.748

Current CPI (Sep. 2019) = 256.7590.

Celgene Quarterly Data

per share eps CPI Adj_EPS
200912 1.026 215.949 1.220
201003 0.970 217.631 1.144
201006 0.649 217.965 0.765
201009 1.188 218.439 1.396
201012 0.875 219.179 1.025
201103 1.095 223.467 1.258
201106 1.212 225.722 1.379
201109 1.703 226.889 1.927
201112 1.958 225.672 2.228
201203 1.971 229.392 2.206
201206 1.856 229.478 2.077
201209 2.278 231.407 2.528
201212 1.501 229.601 1.679
201303 2.264 232.773 2.497
201306 2.985 233.504 3.282
201309 2.467 234.149 2.705
201312 1.585 233.049 1.746
201403 2.617 236.293 2.844
201406 5.850 238.343 6.302
201409 5.136 238.031 5.540
201412 6.328 234.812 6.919
201503 7.585 236.119 8.248
201506 3.907 238.638 4.204
201509 -0.376 237.945 -0.406
201512 8.931 236.525 9.695
201603 14.458 238.132 15.589
201606 10.485 241.018 11.170
201609 3.133 241.428 3.332
201612 8.402 241.432 8.935
201703 17.730 243.801 18.672
201706 22.424 244.955 23.505
201709 21.203 246.819 22.057
201712 -1.909 246.524 -1.988
201803 22.164 249.554 22.804
201806 35.664 251.989 36.339
201809 55.198 252.439 56.143
201812 56.558 251.233 57.802
201903 83.653 254.202 84.494
201906 96.507 256.143 96.739
201909 129.748 256.759 129.748

Add all the adjusted EPS together and divide 10 will get our e10.

Frequently Asked Questions Learn more about E10 →
What does a E10 of ARS0.00 mean?
Celgene (BUE:CELG) has a E10 of ARS0.00 as of Sep. 2019. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Celgene and its competitors.
Is Celgene's E10 too high?
Celgene's current E10 is ARS0.00. Overall, Celgene has a GF Score™ of 10/100, reflecting its overall financial health beyond just this single metric.
How does Celgene's E10 compare to GILD and BIIB?
Celgene's E10 of ARS0.00 can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good E10 for a Drug Manufacturers company?
A good E10 depends on the Drug Manufacturers industry context. However, E10 should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high E10 mean?
A high E10 can signal that a stock is expensive relative to its fundamentals. E10 represents the company's inflation-adjusted earnings per share over a 10-year period. View historical data on Celgene and its competitors. Celgene's current E10 is ARS0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Celgene stock overvalued right now?
Celgene (BUE:CELG) has a current E10 of ARS0.00. The current E10 is ARS0.00. Celgene's overall GF Score™ is 10/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is E10 calculated?
E10 is calculated from a company's financial statements. For Celgene (BUE:CELG), the current E10 is ARS0.00 as of Sep. 2019. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Celgene Business Description

Address 86 Morris Avenue, Summit, NJ, USA, 07901
Celgene is a biopharmaceutical firm that discovers, develops, and markets therapeutics for the treatment of cancer and immunological diseases. Celgene markets Thalomid and Pomalyst to treat multiple myeloma and Revlimid, a less toxic thalidomide derivative, to treat myelodysplastic syndromes, multiple myeloma, and mantle cell lymphoma. Acquisitions have brought MDS drug Vidaza, T-cell lymphoma drug Istodax, and cancer drug Abraxane. The firm's first immunology drug, Otezla, was approved in the U.S. in 2014. Pending acquisitions of Juno and Impact bring additional drugs for Celgene's blood cancer pipeline.